These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1143400)
1. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine. Waldmeier PC; Maître L Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400 [No Abstract] [Full Text] [Related]
2. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Waldmeier PC; Delini-Stula A; Maître L Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359 [TBL] [Abstract][Full Text] [Related]
3. Postnatal development of dopamine deamination in the striatum of the rat. Davis AJ; Holzbauer M; Sharman DF Br J Pharmacol; 1975 Dec; 55(4):558-60. PubMed ID: 1212563 [TBL] [Abstract][Full Text] [Related]
4. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Iurlo M; Leone G; Schilström B; Linnér L; Nomikos G; Hertel P; Silvestrini B; Svensson H Psychopharmacology (Berl); 2001 Dec; 159(1):98-104. PubMed ID: 11797076 [TBL] [Abstract][Full Text] [Related]
5. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. Colzi A; d'Agostini F; Kettler R; Borroni E; Da Prada M J Neural Transm Suppl; 1990; 32():79-84. PubMed ID: 2089114 [TBL] [Abstract][Full Text] [Related]
6. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. Wayment HK; Schenk JO; Sorg BA J Neurosci; 2001 Jan; 21(1):35-44. PubMed ID: 11150317 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Fuller RW; Hemrick-Luecke SK J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. Paterson IA; Juorio AV; Berry MD; Zhu MY J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846 [TBL] [Abstract][Full Text] [Related]
9. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. Demarest KT; Smith DJ; Azzaro AJ J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510 [TBL] [Abstract][Full Text] [Related]
10. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. Yang HY; Neff NH J Pharmacol Exp Ther; 1974 Jun; 189(3):733-40. PubMed ID: 4843170 [No Abstract] [Full Text] [Related]
11. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Gal S; Zheng H; Fridkin M; Youdim MB J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414 [TBL] [Abstract][Full Text] [Related]
12. Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney. Fernandes MH; Soares-da-Silva P J Pharmacol Exp Ther; 1990 Dec; 255(3):1309-13. PubMed ID: 2124622 [TBL] [Abstract][Full Text] [Related]
13. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro]. Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029 [TBL] [Abstract][Full Text] [Related]
14. The effect of a new fluorinated tricyclic neuroleptic drug isofloxythepin on the rat striatal dopamine metabolism. Valchár M; Metysová J; Dlabac A Act Nerv Super (Praha); 1979 Oct; 21(3):130-1. PubMed ID: 42258 [No Abstract] [Full Text] [Related]
15. Effect of selegiline on dopamine concentration in the striatum of a primate. Kaseda S; Nomoto M; Iwata S Brain Res; 1999 Jan; 815(1):44-50. PubMed ID: 9974121 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors. Pettersson F; Svensson P; Waters S; Waters N; Sonesson C J Med Chem; 2012 Apr; 55(7):3242-9. PubMed ID: 22385498 [TBL] [Abstract][Full Text] [Related]
17. Modification of dopamine release by selective inhibitors of MAO-B. Finberg JP; Lamensdorf I; Armoni T Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211 [TBL] [Abstract][Full Text] [Related]
18. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. Finberg JP; Wang J; Bankiewicz K; Harvey-White J; Kopin IJ; Goldstein DS J Neural Transm Suppl; 1998; 52():279-85. PubMed ID: 9564628 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N. Pérez V; Morón J; Pastó M; Unzeta M Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513 [TBL] [Abstract][Full Text] [Related]
20. Age-related changes in the metabolism of neurotransmitters in rat striatum: a microdialysis study. Nakano M; Mizuno T Mech Ageing Dev; 1996 Feb; 86(2):95-104. PubMed ID: 8852930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]